{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:13:29Z","timestamp":1790162009959,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.vaccine.2013.06.050","type":"journal-article","created":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T09:30:46Z","timestamp":1372498246000},"page":"3899-3905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States"],"prefix":"10.1016","volume":"31","author":[{"given":"Harrell W.","family":"Chesson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatus U.","family":"Ekwueme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Saraiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen F.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"RR-2","key":"10.1016\/j.vaccine.2013.06.050_bib0005","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.050_bib0010","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2013.06.050_bib0015","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.050_bib0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjc.6603501","article-title":"Estimating the long-term impact of a prophylactic human papillomavirus 16\/18 vaccine on the burden of cervical cancer in the UK","volume":"96","author":"Kohli","year":"2007","journal-title":"Br J Cancer"},{"issue":"July (20)","key":"10.1016\/j.vaccine.2013.06.050_bib0025","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"issue":"October (26)","key":"10.1016\/j.vaccine.2013.06.050_bib0030","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.050_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2013.06.050_bib0040","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2013.06.050_bib0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.050_bib0050","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.vaccine.2010.10.018","article-title":"Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries","volume":"29","author":"Wong","year":"2011","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2013.06.050_bib0055","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.vaccine.2010.02.019","article-title":"Post-licensure monitoring of HPV vaccine in the United States","volume":"28","author":"Markowitz","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.050_bib0060","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2105\/AJPH.2011.300465","article-title":"Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007\u2013010","volume":"102","author":"Bauer","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0065","first-page":"e1","article-title":"Prevalence of anogenital warts among participants in private health plans in the United States, 2003\u2013010: potential impact of HPV vaccination","author":"Flagg","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2013.06.050_bib0075","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2013.06.050_bib0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"9783","key":"10.1016\/j.vaccine.2013.06.050_bib0085","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2013.06.050_bib0090","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1185\/03007990903136378","article-title":"Assessing incidence and economic burden of genital warts with data from a US commercially insured population","volume":"25","author":"Hoy","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"19","key":"10.1016\/j.vaccine.2013.06.050_bib0095","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Future II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.050_bib0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.vaccine.2013.06.050_bib0105","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"9679","key":"10.1016\/j.vaccine.2013.06.050_bib0110","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0115","series-title":"Efficacy of the quadrivalent HPV vaccine against HPV 6\/11\/16\/18-related genital infection in young men","author":"Palefsky","year":"2008"},{"issue":"5","key":"10.1016\/j.vaccine.2013.06.050_bib0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.vaccine.2013.06.050_bib0125","first-page":"671","article-title":"National and state vaccination coverage among adolescents aged 13 through 17 years \u2013 United States, 2011","volume":"61","author":"Dorell","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2013.06.050_bib0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1071\/SH10001","article-title":"Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia","volume":"8","author":"Gertig","year":"2011","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0135","doi-asserted-by":"crossref","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"Br Med J"},{"issue":"24","key":"10.1016\/j.vaccine.2013.06.050_bib0140","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.vaccine.2012.03.063","article-title":"Factors associated with HPV vaccine uptake in teenage girls: a systematic review","volume":"30","author":"Kessels","year":"2012","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2013.06.050_bib0145","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males \u2013 Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","author":"Centers for Disease Control Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.04.051","article-title":"Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States","author":"Chesson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0155","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2013.06.050_bib0160","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0165","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"Br Med J"},{"issue":"42","key":"10.1016\/j.vaccine.2013.06.050_bib0170","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.050_bib0175","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"Br Med J"},{"issue":"33","key":"10.1016\/j.vaccine.2013.06.050_bib0180","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1016\/j.vaccine.2010.05.056","article-title":"Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis","volume":"28","author":"Van de Velde","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13008426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13008426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T19:00:37Z","timestamp":1539543637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13008426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":36,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0264410X13008426"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}